Synthetic Biology Design Assurance
A single bounded design-assurance review for synthetic-biology programs — spanning circuit design, CRISPR safety, metabolic performance, omics integration and biosafety. One verdict your review board can act on, in place of five separate reports.
Who this is for
Synthetic-biology design review teams
Teams assessing gene-circuit or cell-free synthetic-biology designs who need one reviewable verdict instead of scattered design notes.
CRISPR safety review teams
Teams that need a bounded, evidence-backed read on editing safety before a design moves forward — not a raw-data review.
Metabolic and pathway review teams
Teams comparing pathway performance and yield across candidate designs before committing the next round of budget.
Multi-omics and biosafety reviewers
Teams that need omics-integration and biosafety clearance handled in the same review as the rest of the design, not as an afterthought.
The problem you already have
Multiple design domains still have to resolve to one decision
Circuit design, editing safety, metabolic performance, omics integration and biosafety can arrive as separate review artifacts. A program cannot decide whether a design should advance until those signals are reconciled against the same decision boundary. The review needs one cross-domain record rather than a stack of disconnected conclusions.
One weak signal can undermine an otherwise strong design
A design can look strong on circuit performance while carrying an off-target concern, metabolic bottleneck or other cross-domain inconsistency. If that evidence is reviewed in isolation, the weak signal can surface only after more budget has already been committed. A bounded design review keeps the conflicting evidence visible before the next program decision.
Biosafety must be explicit without turning review into a raw-data handoff
Containment adequacy and biosafety clearance need a defensible answer inside the same review as the technical evidence. That does not require raw biological sequences, full omics datasets, instrument traces or laboratory notebooks to leave your control. S04 is built around the structured summary evidence your team already tracks.
Real-World Operational Scenario: The Design That Passed Four Reviews but Failed the Fifth
Scenario: A synthetic-biology design looks strong in circuit behavior, metabolic output, omics fit and containment planning, but one editing-safety signal remains unresolved.
A design-review board is deciding whether to fund the next experimental stage. Each domain team has produced a different summary, and four reports are favorable.
WITHOUT this gate: The majority of favorable reports can create pressure to advance, while the unresolved safety signal is treated as a side issue rather than a design-level blocker.
WITH this gate: Circuit, CRISPR safety, metabolic, multi-omics and biosafety evidence are mapped to one bounded decision contract. A single unresolved critical domain remains visible as a hold condition, and the board receives one cross-domain verdict instead of five disconnected conclusions.
What BivectorAI Provides
Five-Domain Design Evidence Gate
Maps the structured summary evidence already produced across circuit, editing-safety, metabolic, multi-omics and biosafety review into one bounded design-level decision record.
Cross-Domain Consistency Review
Uses the Part 121 disclosure as technical lineage for circuit topology, off-target context, metabolic constraints and multi-omics integration so contradictory domain signals remain explicit rather than being averaged away.
Critical-Domain Hold Logic
Preserves the principle that one unresolved safety, containment or evidence-critical domain can block promotion even when the remaining domains look favorable.
Research-Only Human Authority Boundary
Returns a design-assurance decision input for human review. Experimental validation, laboratory execution, biosafety authority and final design release remain with the customer.
Prove the Gate Before Broader Integration
Back-test the five-domain gate against frozen historical design reviews before embedding it deeper in the development lifecycle.
Freeze the accepted summary fields, per-domain pass/hold conditions, cross-domain conflict rules and final go/hold/no-go criteria before revealing the historical board disposition. Broader integration is justified only if the same contract reproducibly preserves critical blockers and improves design-review consistency without converting computational assurance into experimental validation.
What you provide
A structured summary of the design across the areas you already evaluate — circuit performance, CRISPR safety, metabolic behavior, omics integration and biosafety level. No raw sequence data, no lab protocols, no design files change hands.
What BivectorAI actually hands you
One bounded cross-domain verdict
A go / hold / no-go design-level read tied to the structured summary evidence supplied across the five review domains.
Domain-by-domain conflict record
A reviewable breakdown showing where circuit, editing-safety, metabolic, multi-omics or biosafety evidence agrees, conflicts or remains insufficient.
Critical hold and human next action
An explicit blocker or escalation record when a safety-critical or evidence-critical domain cannot support promotion, plus the bounded next action for your review board.
Tamper-evident evidence package
A record ID, validity window, timestamp and tamper-evident seal linking the supplied design summaries to the cross-domain verdict and review findings.
How this compares to our narrower metabolic-only check
S04 is the full, multi-domain design-assurance review — circuit, safety, metabolic, omics and biosafety together. Our Synthetic Metabolic Systems Assurance product (S08) is a narrower, single-candidate metabolic and safety check. If you only need that narrower read, ask us about S08 instead.
Compare with S08 — Synthetic Metabolic Systems Assurance →
What we will never ask you for
Synthetic-biology design review can involve sensitive sequence, omics and laboratory evidence. S04 is built around the structured summary evidence your team already has, so raw research datasets and laboratory-execution material stay outside the engagement.
We will never ask you for:
- raw biological sequence datasets;
- raw omics matrices or full experimental datasets;
- raw instrument traces or laboratory notebook content;
- experimental-control or laboratory-execution instructions.
The assessment works entirely from the structured summary evidence you already track across your design review — not from raw research data.
How it actually runs
01 — You share your design summary
Circuit, safety, metabolic, omics and biosafety evidence your team already produces during design review — no new instrumentation required.
02 — We map and validate the fit
During the scoped private integration, we confirm your evidence maps cleanly across all five domains and reject ambiguous mappings rather than silently guess.
03 — You receive the evidence-backed verdict
One bounded verdict spanning circuit, safety, metabolic and biosafety reads, backed by a timestamped, sealed evidence record.
04 — You decide
The assessment informs your review board's decision. It never takes an autonomous action on your design or your data.
Strategic commercial terms
Strategic technology — direct commercial agreement only. No automated checkout applies to this strategic line; every engagement is scoped with you directly.
We do not open with an annual license. The first engagement is a fixed-scope pilot run against one of your own designs. If the assessment doesn't sharpen your review process, there is no reason to move into a broader commercial commitment; you keep the pilot record and stop there.
Single-design pilot
Fixed scope
One design, one evidence-backed cross-domain verdict — quoted per engagement, no ongoing commitment.
Private integration / NRE
On request
Environment setup, data-mapping validation, acceptance evidence and controlled deployment scope.
Annual technology license
On request
Ongoing access within the agreed field, program and deployment boundary.
Program / campaign
On request
Scoped to a single program or campaign where the assessment generates substantial exportable decision value.
Exclusive field-of-use rights, sublicensing, source-level technical data, IP assignment, unusually broad bulk usage, and dedicated infrastructure are negotiated separately and are not included in the annual license.
Scope the S04 engagement
Request S04 Strategic Discussion →Email fallback: contact@bivectorai.com
S04 is delivered through direct strategic engagement, not a self-service public API. No automated checkout is offered for this line.